22Nov 2022
DREAMseq of therapy for <i>BRAF</i>-mutant melanoma

DREAMseq of therapy for <i>BRAF</i>-mutant melanoma

The choice of frontline therapy for patients with advanced-stage BRAF-mutant melanoma has been unclear: responses tend to be more familiar with BRAF-targeted treatment but more durable with immune-checkpoint inhibitors (ICIs). Moreover, the initial use of one strategy might affect responses to the other. Now, data from the phase III DREAMseq trial indicate an optimal treatment sequence.

  • #oncology

Like

Save

Share